Subcutaneous interferon beta-1a has a positive effect on cognitive performance in mildly disabled patients with relapsingĝ€" remitting multiple sclerosis: 2-year results from the COGIMUS study

Francesco Patti, Maria Pia Amato, Stefano Bastianello, Luisa Caniatti, Elisabetta Di Monte, Fausto Lijoi, Benedetta Goretti, Silvia Messina, Orietta Picconi, Maria Rosalia Tola, Maria Trojano

Research output: Contribution to journalArticlepeer-review

Abstract

The effect of interferon (IFN) beta-1a (44 and 22 g subcutaneously [sc] three times weekly [tiw]) on cognition in mildly disabled patients with relapsingĝ€"remitting multiple sclerosis (McDonald criteria; Expanded Disability Status Scale ĝ‰Currency sign4.0) was assessed by validated neuropsychological testing at baseline and at regular intervals for up to 2 years in this ongoing open-label, 3-year study. Year-2 data were available for 356 patients (22 g, n = 175; 44 g, n = 181). The proportion of patients with impaired cognitive function was stable during the study: 21.4% at baseline and 21.6% at 2 years. At 2 years, the proportion of patients with ĝ‰¥3 impaired cognitive tests was significantly lower in the 44 g treatment group (17.0%) compared with the 22 g group (26.5%; p = 0.034), although there was already a trend towards a higher proportion of patients with cognitive impairment in the 22 g group at baseline. Factors associated with impairment in ĝ‰¥ three cognitive tests after 2 years were age (odds ratio [OR]: 1.05; 95% confidence interval [CI]: 1.00ĝ€"1. 09), verbal intelligence quotient (OR: 0.95; 95% CI: 0.92ĝ€"0. 98), and having ĝ‰¥ three impaired cognitive tests at baseline (OR: 11.60; 95% CI: 5.94ĝ€"22.64). These interim results show that IFN beta-1a sc tiw may have beneficial effects on cognitive function as early as 2 years after treatment initiation, but the final 3-year data of the study are required to confirm these results.

Original languageEnglish
Pages (from-to)67-77
Number of pages11
JournalTherapeutic Advances in Neurological Disorders
Volume2
Issue number2
DOIs
Publication statusPublished - Mar 2009

Keywords

  • Cognitive function
  • Cognitive impairment
  • Interferon beta-1a
  • Relapsingĝ€"remitting multiple sclerosis

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Pharmacology

Fingerprint Dive into the research topics of 'Subcutaneous interferon beta-1a has a positive effect on cognitive performance in mildly disabled patients with relapsingĝ€" remitting multiple sclerosis: 2-year results from the COGIMUS study'. Together they form a unique fingerprint.

Cite this